Joel Johnson, MD
Family Medicine · Park River, NDNPI 1528138542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by Amgen at 27.9% of the total. Among family medicine clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Merck$483
- Astellas Pharma US Inc$440
- Pfizer$394
- Sanofi-aventis U.S. LLC$306
- Lilly USA, LLC$217
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,02796%
- Education$2194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 87 | $1,461 |
| Merck | 28 | $483 |
| Astellas Pharma US Inc | 25 | $440 |
| Pfizer | 26 | $394 |
| Sanofi-aventis U.S. LLC | 20 | $306 |
| Lilly USA, LLC | 14 | $217 |
| AbbVie(2 entities) | 11 | $185 |
| Novo Nordisk | 19 | $172 |
| Novartis | 10 | $160 |
| Phathom Pharmaceuticals, Inc. | 8 | $147 |
| Regeneron Healthcare Solutions, Inc. | 6 | $139 |
| E.r. Squibb & Sons, L.L.C. | 8 | $125 |
| Smith+Nephew | 7 | $108 |
| Johnson & Johnson(2 entities) | 5 | $72 |
| Eisai Inc. | 4 | $70 |
| Kyowa Kirin, Inc. | 4 | $65 |
| GSK | 4 | $61 |
| Neurocrine Biosciences, Inc. | 4 | $60 |
| Bayer | 3 | $50 |
| AstraZeneca | 3 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Organogenesis Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Verona Pharma, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $25 |
| Abbott | 1 | $22 |
| Medtronic | 1 | $20 |
| Sanofi | 1 | $20 |
| Cepheid | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
How this compares
$5,246 in reported general payments places this provider in the 90th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $242,772 |
| OzempicSemaglutide | 83 | $86,764 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 11 | $84,060 |
| JanuviaSitagliptin Phosphate | 48 | $40,344 |
| XareltoRivaroxaban | 57 | $39,453 |
| Repatha SureclickEvolocumab | 55 | $34,410 |
| MyrbetriqMirabegron | 55 | $32,245 |
| VraylarCariprazine Hcl | 16 | $23,224 |
| JardianceEmpagliflozin | 17 | $22,732 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $21,072 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $18,919 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $17,937 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,922 |
| TrulicityDulaglutide | 13 | $15,579 |
| FarxigaDapagliflozin Propanediol | 11 | $15,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Effexor Xr | $394 | $252,296402 claims |
| Novo NordiskOzempic, Rybelsus | $172 | $98,30394 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $61 | $67,221141 claims |
| MerckJanuvia, Janumet | $483 | $48,73361 claims |
| Johnson & JohnsonXarelto | $72 | $39,45357 claims |
| AbbVieVraylar, Linzess | $185 | $33,52633 claims |
| Astellas Pharma US IncMyrbetriq | $440 | $32,24555 claims |
| AstraZenecaFarxiga, Brilinta | $43 | $28,78134 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $306 | $18,91920 claims |
| Lilly USA, LLCTrulicity | $217 | $15,57913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Park River
- Kristi MidgardenPark River$3K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
- Eric JohnsonGrand Forks$52K
- Stuart TopleyFargo$24K
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.